New drug duo aims to tame tough liver cancers after other treatments fail
NCT ID NCT06789848
Summary
This study is testing whether a combination of two immunotherapy drugs, ligufalimab and cadonilimab, can help control advanced liver or bile duct cancers that have worsened after prior immunotherapy. It will enroll about 64 adults whose cancer has spread and is no longer responding to standard treatments. The main goal is to see if the tumor shrinks in response to this new drug pair.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Texas Southwestern Medical Center
RECRUITINGDallas, Texas, 75390, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.